Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells

(2015) Florian Rothweiler et al.   NEOPLASIA

Selective Enrichment of Hepatocellular Cancer Stem Cells by Chemotherapy

(2013) S Tan et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation

(2011) Jane M Valentine et al.   BMC CANCER

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

(2011) T. Van Maerken et al.   MOLECULAR CANCER THERAPEUTICS

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

(2011) M H Aziz et al.   ONCOGENE

Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1

(2010) Ramesh M. Ray et al.   APOPTOSIS

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

(2010) J. Carr-Wilkinson et al.   CLINICAL CANCER RESEARCH

Reactivation of p53: from peptides to small molecules

(2010) Christopher J. Brown et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

DNA damage response to the Mdm2 inhibitor Nutlin-3

(2009) Rajeev Verma et al.   BIOCHEMICAL PHARMACOLOGY

Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines

(2009) Martin Michaelis et al.   BIOCHEMICAL PHARMACOLOGY

MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53

(2009) J A Canner et al.   BRITISH JOURNAL OF CANCER

Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3

(2009) M. Michaelis et al.   CANCER RESEARCH

Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells

(2009) M. Miyachi et al.   CLINICAL CANCER RESEARCH

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

(2009) L. M. Ellis et al.   CLINICAL CANCER RESEARCH

Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53

(2009) Tom Van Maerken et al.   JNCI-Journal of the National Cancer Institute

Transient Nutlin-3a Treatment Promotes Endoreduplication and the Generation of Therapy-Resistant Tetraploid Cells

(2008) H. Shen et al.   CANCER RESEARCH

A Multicolor Panel of Novel Lentiviral “Gene Ontology” (LeGO) Vectors for Functional Gene Analysis

(2008) Kristoffer Weber et al.   MOLECULAR THERAPY

The role of p53 in pigmentation, tanning and melanoma

(2008) Neil F. Box et al.   Pigment Cell & Melanoma Research

Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties

(2008) Vera Levina et al.   PLoS One